Terns Pharmaceuticals Return On Asset vs. Beta

TERN Stock  USD 5.76  0.05  0.88%   
Based on Terns Pharmaceuticals' profitability indicators, Terns Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Terns Pharmaceuticals' ability to earn profits and add value for shareholders. As of the 22nd of November 2024, Price To Sales Ratio is likely to drop to 142.92. In addition to that, EV To Sales is likely to drop to 104.76. At this time, Terns Pharmaceuticals' Net Interest Income is very stable compared to the past year. As of the 22nd of November 2024, Interest Income is likely to grow to about 13.5 M, while Accumulated Other Comprehensive Income is likely to drop (19.9 K).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.390.44
Fairly Down
Slightly volatile
For Terns Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Terns Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Terns Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Terns Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Terns Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.18)
Revenue Per Share
0.035
Return On Assets
(0.19)
Return On Equity
(0.28)
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Terns Pharmaceuticals Beta vs. Return On Asset Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Terns Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Terns Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Terns Pharmaceuticals is rated third in return on asset category among its peers. It is rated below average in beta category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Terns Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Terns Beta vs. Return On Asset

Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Terns Pharmaceuticals

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.19
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Terns Pharmaceuticals

Beta

 = 

Covariance

Variance

 = 
-0.33
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.

Terns Beta Comparison

Terns Pharmaceuticals is currently under evaluation in beta category among its peers.

Beta Analysis

As returns on the market increase, returns on owning Terns Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Terns Pharmaceuticals is likely to outperform the market.

Terns Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Terns Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Terns Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Terns Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Terns Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-19 K-19.9 K
Net Interest Income12.9 M13.5 M
Interest Income12.9 M13.5 M
Operating Income-102.6 M-97.4 M
Net Loss-90.2 M-85.7 M
Income Before Tax-90 M-85.5 M
Total Other Income Expense Net12.6 M13.2 M
Net Loss-54.3 M-57 M
Net Loss-90.2 M-85.7 M
Income Tax Expense239 K335.7 K
Non Operating Income Net Other1.8 M1.6 M
Change To Netincome12.4 M13 M
Net Loss(1.27)(1.33)
Income Quality 0.75  0.94 
Net Income Per E B T 1.00  0.80 

Terns Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Terns Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Terns Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Terns Pharmaceuticals' important profitability drivers and their relationship over time.

Use Terns Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Terns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Terns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Terns Pharmaceuticals Pair Trading

Terns Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Terns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Terns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Terns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Terns Pharmaceuticals to buy it.
The correlation of Terns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Terns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Terns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Terns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Terns Pharmaceuticals position

In addition to having Terns Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Driverless Cars Thematic Idea Now

Driverless Cars
Driverless Cars Theme
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock:
Check out World Market Map.
To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
To fully project Terns Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Terns Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Terns Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Terns Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Terns Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Terns Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Terns Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.